Abstract
The trypanocidal effect of six lignan lactones, (−)-cubebin (1), (−)-O-methyl cubebin (2), (−)-O-benzyl cubebin (3), (−)-6,6′-dinitrohinokinin (4), (−)-hinokinin (5) and dimethoxymorelensin (6), previously synthesized by our research group, was evaluated in vitro and in vivo. The compounds with higher anti-epimastigote activity were screened against intracellular amastigote of Trypanosoma cruzi. Among these, compound 5 was selected to be assayed in vivo. It was observed that compounds 5, 6 and 2 showed higher trypanocidal activity against epimastigote forms of T. cruzi, displaying inhibitory concentration (IC50) values of 0.67, 3.89 and 31.35 μM, respectively. These compounds were also evaluated against intracellular amastigote forms of T. cruzi, with five displaying similar activity to benznidazole. In vivo assays showed significant reduction of parasitaemia after administration of five in mice infected.
Similar content being viewed by others
References
Bastos JK, Gottlieb OR, Sarti SJ, Santos Filho D (1996) The isolation of lignans and sesquiterpenoids from leaves of Zanthoxylum naranjillo. Nat Prod Lett 9:65–70
Bastos JK, Albuquerque S, Silva ML (1999) Evaluation of the trypanocidal activity of lignans isolated from the leaves of Zanthoxylum naranjillo. Planta Med 65(6):541–544
Bode JW, Doyle MP, Protopopova MN, Zhou QL (1996) Intramolecular regioselective insertion into unactivated prochiral carbon–hydrogen bonds with diazoacetates catalyzed by chiral dirhodium(II) carboxamidates. Highly enantioselective total synthesis of natural lignan lactones. J Org Chem 61:9146–9155
Buckner FS, Verlinde CL, La Flamme AC, Van Voorhis WC (1996) Efficient technique for screening drugs for activity against Trypanosoma cruzi using parasites expressing betagalactosidase. Antimicrob Agents Chemother 40:2592–2597
Brener Z (1962) Therapeutic activity and criterion of cure on mice experimentally infected with Trypanosoma cruzi. Rev Inst Med Trop São Paulo 4:389–396
Castellani O, Ribeiro LV, Fernandes JF (1967) Differentiation of Trypanosoma cruzi in culture. J Protozool 14(3):447–451
Croft SL (1997) The current status of antiparasite chemotherapy. Parasitology 114(Suppl):3–15
da Silva R, de Souza GH, da Silva AA, de Souza VA, Pereira AC, Royo Vde A, E Silva ML, Donate PM, de Matos Araujo AL, Carvalho JC, Bastos JK (2005) Synthesis and biological activity evaluation of lignan lactones derived from (−)-cubebin. Bioorg Med Chem Lett 15(4):1033–1037
de Castro SL (1993) The challenge of Chagas’ disease chemotherapy: an update of drugs assayed against Trypanosoma cruzi. Acta Trop 53(2):83–98
de Souza VA, da Silva R, Pereira AC, Royo Vde A, Saraiva J, Montanheiro M, de Souza GH, da Silva Filho AA, Grando MD, Donate PM, Bastos JK, Albuquerque S, e Silva ML (2005) Trypanocidal activity of (−)-cubebin derivatives against free amastigote forms of Trypanosoma cruzi. Bioorg Med Chem Lett 2005 15(2):303–307
Docampo R (2001) Recent developments in the chemotherapy of Chagas disease. Curr Pharm Des 7(12):1157–1164
Filardi LS, Brener Z (1987) Susceptibility and natural resistance of Trypanosoma cruzi strains to drugs used clinically in Chagas disease. Trans R Soc Trop Med Hyg 81(5):755–759
Heleno VCG, da Silva R, Pedersoli S, Albuquerque S, Bastos JK, e Silva MLA, Donate PM, da Silva GVJ, Lopes JLC (2006) Detailed 1H and 13C NMR structural assignment of three biologically active lignan lactones. Spectrochim Acta Part A 63:234–239
Martinez-Diaz RA, Escario JA, Nogal-Ruiz JJ, Gomez-Barrio A (2001) Biological characterization of Trypanosoma cruzi strains. Mem Inst Oswaldo Cruz 96(1):53–59
Muelas-Serrano S, Le-Senne A, Fernandez-Portillo C, Nogal JJ, Ochoa C, Gomez-Barrio A (2002) In vitro and in vivo anti-Trypanosoma cruzi activity of a novel nitro-derivative. Mem Inst Oswaldo Cruz 97(4):553–557
Murta SM, Gazzinelli RT, Brener Z, Romanha AJ (1998) Molecular characterization of susceptible and naturally resistant strains of Trypanosoma cruzi to benznidazole and nifurtimox. Mol Biochem Parasitol 93(2):203–214
Ochoa C, Perez E, Perez R, Suarez M, Ochoa E, Rodriguez H, Gomez Barrio A, Muelas S, Nogal JJ, Martinez RA (1999) Synthesis and antiprotozoan properties of new 3,5-disubstituted-tetrahydro-2H-1,3,5-thiadiazine-2-thione derivatives. Arzneim-Forsch 49(9):764–769
Paulino M, Iribarne F, Dubin M, Aguilera-Morales S, Tapia O, Stoppani AO (2005) The chemotherapy of Chagas’ disease: an overview. Mini Rev Med Chem 5(5):499–519
Rodriques Coura J, de Castro SL (2002) A critical review on Chagas’ disease chemotherapy. Mem Inst Oswaldo Cruz 97(1):3–24
Rolon M, Seco EM, Vega C, Nogal JJ, Escario JA, Gomez-Barrio A, Malpartida F (2006) Selective activity of polyene macrolides produced by genetically modified Streptomyces on Trypanosoma cruzi. Int J Antimicrob Agents 28(2):104–109
Souza GH, da Silva Filho AA, de Souza VA, Pereira AC, Royo Vde A, e Silva ML, da Silva R, Donate PM, Carvalho JC, Bastos JK (2004) Analgesic and anti-inflammatory activities evaluation of (−)-O-acetyl, (−)-O-methyl, (−)-O-dimethylethylamine cubebin and their preparation from (−)-cubebin. Farmaco 59(1):55–61
Urbina JA, Docampo R (2003) Specific chemotherapy of Chagas’ disease: controversies and advances. Trends Parasitol 19(11):495–501
Vega C, Rolon M, Martinez-Fernandez AR, Escario JA, Gomez-Barrio A (2005) A new pharmacological screening assay with Trypanosoma cruzi epimastigotes expressing β-galactosidase. Parasitol Res 95(4):296–298
WHO (2003) http://www.who.int/tdr/dw/chagas2003.htm
Acknowledgment
We would like to thank FAPESP for the financial support. The undertaken experiments comply with the current laws of the country in which they were performed.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Saraiva, J., Vega, C., Rolon, M. et al. In vitro and in vivo activity of lignan lactones derivatives against Trypanosoma cruzi . Parasitol Res 100, 791–795 (2007). https://doi.org/10.1007/s00436-006-0327-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00436-006-0327-4